MiniMed® Connect Now Available from Medtronic for Smartphone Access to Personal Diabetes Data
DUBLIN – September 28, 2015 – Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced U.S. commercial availability of MiniMed Connect, the first and only product to enable people with diabetes to discreetly and conveniently view their insulin pump and continuous glucose monitoring (CGM) information on a smartphone.
MiniMed Connect provides greater convenience for people with diabetes, greater peace of mind for their care partners, and more convenient access to diabetes data for healthcare teams.
• People with diabetes can discreetly view their diabetes information on a smartphone app.
• MiniMed Connect also allows care partners to view and monitor this diabetes information via CareLink Personal, Medtronic’s therapy management software. It delivers preset text notifications to care partners when the person with diabetes experiences sugar levels that go too high or too low or when an alarm on the pump isn’t cleared.
• With patient permission, and as arranged with their healthcare providers, there can be convenient access to diabetes data in the CareLink reports.
“I tested MiniMed Connect during a recent hike, and it was great to just look at my phone and watch my glucose levels during the trek,” said Karen Graffeo, blogger at Bitter-Sweet. “Strenuous exercise frequently causes my sugar levels to drop, and this trail was tougher than I anticipated. The convenient access to my sensor information was such a huge help; this was the first hike I’ve made it through without going low.”
MiniMed Connect is compatible with both the MiniMed® 530G system and the MiniMed® Revel™ system. The related smartphone app will initially be available with iOS devices. Medtronic is working with Samsung to develop an app for Android and optimized experiences on Samsung mobile devices. This is part of an overall strategic partnership between Medtronic and Samsung to explore and develop solutions that deliver greater convenience and discretion for people with diabetes and their care partners.
“Effective management of diabetes requires an engaged team of participants, and MiniMed Connect serves to inform and involve people with diabetes, their loved ones and their health care professionals,” said Annette Bruls, President of the Diabetes Service and Solutions business at Medtronic. “Safe and secure sharing of critical diabetes data is an important step for Medtronic as we transform into a holistic diabetes management company.”
Medtronic’s vision is to transform diabetes care, together for greater freedom and better health. This vision is centered around a deep-rooted belief in delivering solutions so that people with diabetes can live their exceptional lives. MiniMed Connect achieves this objective and is also a further demonstration of how Medtronic is moving beyond insulin pumps and CGM devices and integrating leading consumer technologies, data and informatics to enable better therapy decision-making and care.
To place an order for MiniMed Connect, or to learn more, visit http://www.medtronicdiabetes.com/products/minimed-connect or call 1-800-646-4633.
About the Diabetes Group at Medtronic (www.medtronicdiabetes.com)
Medtronic is working together with the global community to change the way people manage diabetes. The company aims to transform diabetes care by expanding access, integrating care and improving outcomes, so people living with diabetes can enjoy greater freedom and better health.
Medtronic plc (www.medtronic.com), headquartered in Dublin, Ireland, is among the world’s largest medical technology, services and solutions companies – alleviating pain, restoring health and extending life for millions of people around the world. Medtronic employs more than 85,000 people worldwide, serving physicians, hospitals and patients in more than 160 countries. The company is focused on collaborating with stakeholders around the world to take healthcare Further, Together.
Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.